PTPN11 (protein tyrosine phosphatase, non-receptor type, 11) by Tartaglia, M & Gelb, BD









Atlas Genet Cytogenet Oncol Haematol. 2005; 9(2)  
 
125 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
OPEN ACCESS JOURNAL AT INIST-CNRS 
PTPN11 (Protein tyrosine phosphatase, non-
receptor type, 11) 
Marco Tartaglia, Bruce D Gelb 
Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanitá, Rome, Italy (MT); 
Departments of Pediatrics and Human Genetics, Mount Sinai School of Medicine, New York, USA (BDG) 
 
Published in Atlas Database: February 2005 
Online updated version: http://AtlasGeneticsOncology.org/Genes/PTPN11ID41910ch12q24.html 
DOI: 10.4267/2042/38180 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2005 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Identity 
Other names: SHP-2; SH-PTP2 (Src homology 2 
domain-containing protein tyrosine phosphatase 2); 
PTP2C (Protein tyrosine phosphatase 2C); BPTP3 
HGNC (Hugo): PTPN11 
Location: 12q24.1 
Local order: centromere - FLJ34154 - RPL6 - 
PTPN11 - RPH3A - OAS1 – telomere. 
DNA/RNA 
Description 
The PTPN11 gene is divided in 16 exons. Exon 1 
contains the 5' untranslated region and the translation 
initiation ATG, and a few additional codons. Exon 15 
contains the stop codon and exon 16 contains a major 
portion of the 3' untranslated region. Other features of 
the PTPN11 gene, such as the promoter region and 
enhancer elements have not been delineated. 
Transcription 
A 7.0-kb transcript is detected in several tissues (heart, 
brain, lung, liver, skeletal muscle, kidney, and 
pancreas) with highest steady-state levels in heart and 
skeletal muscle. The predominant human PTPN11 
mRNA contains an open reading frame of 1,779 bases, 
resulting in a predicted protein of 593 amino acid 
residues. A second mRNA containing 12 additional 
base pairs (exon 11) has been identified. Little 




A number of PTPN11-related processed pseudogenes, 
i.e. with no apparent exon structure, have been 
documented in the human genome. All the pseudogenes 
share >92% nucleotide identity with the PTPN11 
cDNA (including the 5'-UTR and 3'-UTR), but harbour 
frameshift mutations and multiple stop codons. Three 
of the five pseudogenes appear to be expressed with 
distinct tissue distributions and expression levels. 
Protein 
Description 
SHP-2 is a member of a small subfamily of 
cytoplasmic Src homology 2 (SH2) domain-containing 
protein tyrosine phosphatases. Both the N-SH2 and C-
SH2 domains selectively bind to short amino acid 
motifs containing a phosphotyrosyl residue and 
promote SHP-2 association with activated receptors 
and other signaling partners. Crystallographic data 
indicate that the N-SH2 domain also interacts with the 
PTP domain using a separate site. As these subdomains 
show negative cooperativity, the N-SH2 domain 
functions as an intramolecular switch controlling SHP-
2 catalytic activation. Specifically, the N-SH2 domain 
interacts with the PTP domain basally, blocking the
catalytic site. Binding of the N-SH2 phosphopeptide-
binding site to the phosphotyrosyl ligand promotes a 
conformational change of the domain that weakens the 
auto-inhibiting intramolecular interaction, making the 














Widely expressed in both embryonic and adult tissue. 
Localisation 
Cytoplasmic. It binds to activated cell surface 
receptors, cell adhesion molecules and scaffolding 
adapters. 
Function 
SHP-2 functions as an intracellular signal transducer. It 
positively modulates signal flow in most 
circumstances, but can also function as negative 
regulator depending upon its binding partner and 
interactions with downstream signaling networks. SHP-
2 positively controls the activation of the RAS/MAPK 
cascade induced by several growth factors, and 
negatively regulates JAK/STAT signaling. In most 
cases, SHP-2's function in intracellular signaling 
appears to be immediately proximal to activated 
receptors and upstream to RAS. The mechanisms of 
SHP-2's action and its physiological substrates are still 
poorly defined. However, both membrane translocation 
and PTPase activity are required for SHP-2 function. 
SHP-2 is required during development. Embryos 
nullizygous for Shp-2 have defects in gastrulation and 
mesodermal patterning resulting in severe 
abnormalities in axial and paraxial mesodermal 
structures. Shp-2 function is also required for 
development of terminal and skeletal structures, 
semilunar valvulogenesis in the heart, and 
hematopoiesis. 
 
PTPN11 genomic organization and SHP-2 domain structure: 
Figure 1 : (A) The PTPN11 gene and SHP-2 domain characterization. The coding exons are shown as numbered filled boxes. The 
functional domains of the protein, comprising two tandemly arranged SH2 domains at the N terminus (N-SH2 and C-SH2) followed by a 
protein tyrosine phosphatase (PTP) domain, are shown below. Numbers below the domain structure indicate the amino-acid boundaries 
of those domains. (B) Three-dimensional structure of SHP-2 in its catalytically inactive conformation, as determined by Hof et al. (1998). 
Residues involved in catalysis are shown (space fill). 
Figure 2 : Location of SHP-2 mutated residues in human disease. (A) Noonan syndrome and LEOPARD syndrome (germ-line origin; 
N=224); (B) Noonan syndrome with juvenile myelomonocytic leukemia (germ-line origin; N=11); (C) hematologic malignancies, including 
juvenile myelomonocytic leukemia, acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes and chronic 
myelomonocytic leukemia (somatic origin; N=97). The pictures show the C trace of SHP-2 in its catalytically inactive conformation. 
Affected residues are indicated with their side chains as black sticks. 










PTPN6 (protein tyrosine phosphatase, non-receptor 
type, 6) previously known as SHP1 or SHP-1 (Src 




At least two distinct classes of PTPN11 mutations have 
been identified in humans. 
The first group, which has germ-line origin, causes 
Noonan syndrome and closely related developmental 
disorders. 
The second group, acquired as a somatic event, has 
been documented in a heterogeneous group of 
hematologic malignancies and pre-leukemic disorders, 
and rarely in certain solid tumors. 
The vast majority of mutations affect residues residing 
at or close to the interface between the N-SH2 and PTP
domains. Increasing evidence supports that both germ-
line and somatic mutations promote SHP-2 gain-of-
function by destabilizing the catalytically inactive 
conformation of the protein, and prolong signal flux 
through the RAS/MAPK pathway in a ligand-
dependent manner. 
A mouse model bearing the NS-causative D61G 
mutation in the Ptpn11 gene has been recently 
generated and characterized. The Ptpn11D61G/D61G 
genotype is embryonic lethal. At day E13.5, these 
embryos are grossly edematous and hemorrhagic, have 
diffuse liver necrosis and severe cardiac defects. 
Heterozygous embryos exhibit cardiac defects, 
proportionate growth failure and perturbed craniofacial 
development. Hematologic anomalies include a mild 
myeloproliferative disease. Ptpn11D61G/+ embryonic 
fibroblasts exhibit a three-fold increased Shp-2 activity 
and increased association of Shp-2 with Gab1 after 
stimulation with EGF. Cell culture and whole embryo 
studies reveal that increased RAS/MAPK signaling is 
variably present, appearing to be cell-context specific. 
Germinal 
Selection: 124A>G (T42A), 179-181delGTG 
(delGly60), 181-183delGAT (delAsp61), 182A>G 
(D61G), 184T>G (Y62D), 188A>G (Y63C), 214G>T 
(A72S), 215C>G (A72G), 218C>T (T73I), 228G>T,C 
(E76D), 236A>G (N79R), 317A>C (D106A), 836A>G 
(Y279C), 922A>G (N308D), 1403C>T (T468M), 
1510A>G (M504V). 
Somatic 
Selection: 181G>T (D61Y), 182A>T (D61V), 205G>A 
(E69K), 211-213TTT>AAA (F71K), 214G>A (A72T), 
215C>T (A72V), 226G>A (E76K), 226G>C (E76Q), 
227A>T (E76V), 227A>G (E76G), 227A>C (E76A),  
1471C>T (P491S), 1472C>T (P491L), 1504T>C 
(S502P), 1504T>G (S502A), 1520C>A (T507K), 
1528C>A (Q510K). 
Implicated in 
Noonan syndrome, Noonan-like/multiple 
giant cell lesion syndrome and 
LEOPARD syndrome 
Note 
Germ-line origin. Gain-of-function mutations. 
Increased basal protein tyrosine phosphatase activity. 
Prolonged ligand-dependent activation of the 
RAS/MAPK cascade. 
Disease 
Noonan syndrome is a genetically heterogeneous and 
clinically variable developmental disorder defined by 
short stature, facial dysmorphism and a wide spectrum 
of congenital heart defects. The distinctive facial 
features consist of a broad forehead, hypertelorism, 
down-slanting palpebral fissures, ptosis, high-arched 
palate and low-set, posteriorly rotated ears. 
Cardiovascular abnormalities, primarily pulmonic 
stenosis and hypertrophic cardiomyopathy, are present 
in up to 85% of affected individuals. Additional 
relatively frequent features are multiple skeletal 
defects, webbed neck, mental retardation, 
cryptorchidism and bleeding diathesis. Children with 
Noonan syndrome are predisposed to a spectrum of 
hematologic abnormalities, including transient 
monocytosis, thrombocytopenia and rarely juvenile 
myelomonocytic leukemia and acute leukemia. 
Juvenile myelomonocytic leukemia, 
acute myeloid leukemia, acute 
lymphoblastic leukemia, 
myelodysplastic syndromes, chronic 
myelomonocytic leukemia, melanoma, 





No data are currently available. 
Oncogenesis 
Gain-of-function mutations. Increased basal protein 
tyrosine phosphatase activity. Prolonged ligand-
dependent activation of the RAS/MAPK cascade. 
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